Pharmacokinetic Changes and Influencing Factors of Polymyxin B in Different ECMO Modes

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2024 Dec 30

PMID 39734740

Authors

Mi Xu

Na Chen

Yong-Wei Yu

Xiang-Ying Pan

Tong Li

Affiliations

Soon will be listed here.

Abstract

Purpose: With the development of extracorporeal membrane oxygenation (ECMO) technology, the duration of ECMO support has gradually increased, leading to an increased risk of ECMO-related bacterial resistance. Polymyxin B (PMB) is used to treat drug-resistant bacterial infections. However, the pharmacokinetic (PK) parameters of antibiotics may change during ECMO, resulting in over- or under-exposure. This study aimed to clarify the changes in PK parameters and identify factors influencing PMB levels in patients receiving venovenous or venoarterial ECMO.

Patients And Methods: A prospective PK study was performed in 11 patients receiving ECMO with resistant bacteria. After reaching a steady state, the drug concentrations of PMB pre- and post-oxygenator were measured. Nonlinear mixed-effects modelling was used to construct a population PK model for PMB. Microbial results were assessed using repeated cultures at the end of treatment. Semiquantitative microbial culture results were used to form clearance and uncleared groups.

Results: The PMB concentrations were not significantly different between pre- and post-oxygenator. A two-compartment model best described the PK of PMB. ECMO flow rate was included as a covariate of clearance (CL). Continuous renal replacement therapy (CRRT) were included as covariates on the volume of the central compartment. The PK parameters central compartment, volume of the peripheral compartment, CL, and inter-compartmental clearance or flow rate(Q) were 20.41 L, 9.86 L, 3.75 L/h, and 3.82 L/h. 7 patients (63.64%) had two consecutive negative bacterial cultures at discharge. The C shows a significant difference between clearance group (2.26±0.72) and uncleared group (1.25±0.24), P<0.05.

Conclusion: There were no significant differences in PMB concentrations between pre- and post-oxygenator. The PK of PMB may be altered in patients receiving CRRT-ECMO. The ECMO flow rate is strongly correlated with the CL. The C is correlated with the bacterial clearance rate. In clinical practice, increasing the incidence of therapeutic drug monitoring may improve the clinical outcomes.

References

Gao X, Wang W . The Etiological and Drug Resistance Characteristics of Multidrug-Resistant Pathogens in Patients Requiring Extracorporeal Membrane Oxygenation: A Retrospective Cohort Study. Infect Drug Resist. 2023; 16:4929-4941. PMC: 10402724. DOI: 10.2147/IDR.S421413. View

Pi M, Cai C, Zuo L, Zheng J, Zhang M, Lin X . Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients. J Antimicrob Chemother. 2023; 78(3):792-801. DOI: 10.1093/jac/dkad012. View

Wildschut E, Ahsman M, Allegaert K, Mathot R, Tibboel D . Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010; 36(12):2109-16. PMC: 2981740. DOI: 10.1007/s00134-010-2041-z. View

Surovoy Y, Burkin M, Galvidis I, Bochkov P, Oganesyan A, Tsarenko S . Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation. J Antimicrob Chemother. 2022; 77(5):1379-1384. DOI: 10.1093/jac/dkac021. View

Antonia K, Anastasia A, Tesseromatis C . Stress can affect drug pharmacokinetics via serum/tissues protein binding and blood flow rate alterations. Eur J Drug Metab Pharmacokinet. 2011; 37(1):1-7. DOI: 10.1007/s13318-011-0077-2. View

Ye Q, Wang Q, Chen W, Zhang R, Chen Z, Li P . The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation. J Clin Pharm Ther. 2022; 47(10):1608-1618. DOI: 10.1111/jcpt.13711. View

Tamma P, Aitken S, Bonomo R, Mathers A, van Duin D, Clancy C . Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. 2023; . DOI: 10.1093/cid/ciad428. View

Mahmoud A, Avedissian S, Al-Qamari A, Bohling T, Pham M, Scheetz M . Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study. Clin Pharmacokinet. 2020; 59(12):1575-1587. PMC: 7704765. DOI: 10.1007/s40262-020-00902-1. View

Lo Coco V, Lorusso R, Raffa G, Malvindi P, Pilato M, Martucci G . Clinical complications during veno-arterial extracorporeal membrane oxigenation in post-cardiotomy and non post-cardiotomy shock: still the achille's heel. J Thorac Dis. 2019; 10(12):6993-7004. PMC: 6344687. DOI: 10.21037/jtd.2018.11.103. View

10.

Ha M, Sieg A . Evaluation of Altered Drug Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation. Pharmacotherapy. 2016; 37(2):221-235. DOI: 10.1002/phar.1882. View

11.

Wang S, Chennupati R, Kaur H, Iring A, Wettschureck N, Offermanns S . Endothelial cation channel PIEZO1 controls blood pressure by mediating flow-induced ATP release. J Clin Invest. 2016; 126(12):4527-4536. PMC: 5127677. DOI: 10.1172/JCI87343. View

12.

Li X, Wang L, Wang H, Hou X . Outcome and Clinical Characteristics of Nosocomial Infection in Adult Patients Undergoing Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. Front Public Health. 2022; 10:857873. PMC: 9268548. DOI: 10.3389/fpubh.2022.857873. View

13.

Shirejini S, Carberry J, McQuilten Z, Burrell A, Gregory S, Hagemeyer C . Current and future strategies to monitor and manage coagulation in ECMO patients. Thromb J. 2023; 21(1):11. PMC: 9878987. DOI: 10.1186/s12959-023-00452-z. View

14.

Nation R, Garonzik S, Thamlikitkul V, Giamarellos-Bourboulis E, Forrest A, Paterson D . Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2016; 64(5):565-571. PMC: 5850520. DOI: 10.1093/cid/ciw839. View

15.

Wang P, Liu P, Zhang Q, Yuan W, Wang D, Zhang X . Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother. 2022; 77(11):3000-3008. DOI: 10.1093/jac/dkac265. View

16.

Duceppe M, Kanji S, Do A, Ruo N, Cavayas Y, Albert M . Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Adults During Extracorporeal Membrane Oxygenation: A Systematic Review. Drugs. 2021; 81(11):1307-1329. DOI: 10.1007/s40265-021-01557-3. View

17.

Manchandani P, Dubrovskaya Y, Gao S, Tam V . Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016; 60(11):6980-6982. PMC: 5075123. DOI: 10.1128/AAC.00702-16. View

18.

Palmer M, Andrews L, Abbey T, Dahlquist A, Wenzler E . The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A review. Front Pharmacol. 2022; 13:888079. PMC: 9359604. DOI: 10.3389/fphar.2022.888079. View

19.

Bougle A, Dujardin O, Lepere V, Ait Hamou N, Vidal C, Lebreton G . PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. Anaesth Crit Care Pain Med. 2019; 38(5):493-497. DOI: 10.1016/j.accpm.2019.02.015. View

20.

Lorusso R, Whitman G, Milojevic M, Raffa G, McMullan D, Boeken U . 2020 EACTS/ELSO/STS/AATS expert consensus on post-cardiotomy extracorporeal life support in adult patients. J Thorac Cardiovasc Surg. 2020; 161(4):1287-1331. DOI: 10.1016/j.jtcvs.2020.09.045. View